You are here

USE OF ADIPOSE-DERIVED PREADIPOCYTES IN BONE DISOREDERS

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: N/A
Agency Tracking Number: 2R44AR045856-02
Amount: $0.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2001
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
801 CAPITOLA DR, STE 8
DURHAM, NC 27713
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JEFFREY GIMBLE
 () -
Business Contact
Phone: (919) 433-1100
Email: BWILKISON@ZEN-BIO.COM
Research Institution
N/A
Abstract

Non-healing bone fractures and periodontal bone loss constitute significant clinical
problems with few approved medical options. Bone repair is enhanced by the
presence of osteoblasts or osteoblastic precursor cells. Subcutaneous adipose tissue
is a plentiful, accessible, and replenishable source of human stromal cells for
transplantation. In Phase I of this SBIR, we tested the hypothesis that human adipose
tissue-derived stromal cells are capable of osteoblast function. Substantial in vitro
data indicates that these stromal cells differentiate into cells biochemically and
morphologically similar to osteoblasts. The ability of these cells to form bone in vivo
was examined as well. Phase II of this SBIR will extend these in vivo experiments.
Specific Aim 1 examines the ability of human adipose tissue-derived stromal cells to
form ectopic bone in hydroxyapatite ceramic cubes implanted subcutaneously in
immunodeficient mice. Specific Aim 2 explores whether the introduction of a
modified bone morphogenetic protein receptor will enhance mineralization by these
cells in vitro. Specific Aim 3 will determine if these modified bone morphogenetic
protein receptor expressing stromal cells form bone more rapidly and efficiently than
control cells using the in vivo murine model described in Aim 1. Together, these
studies will provide a strong foundation for pre-clinical experiments in a large
animal (canine) fracture repair model.
PROPOSED COMMERCIAL APPLICATION:
This technology will provide a cost-effective alternative source of stromal cells
capable of osteoblast differentiation for autologous and allogeneic transplantation
into sites of bone defects and fractures. This has commercial application to
orthopedic and periodontal surgical treatments of joint replacement, fracture repair,
and bone resorption secondary to tooth decay.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government